Best of Targeted Therapies of Lung Cancer (TTLC) 2026-Recording

Video Transcription

Video Summary

This ISLC “Best of TTLC 2026” webinar, moderated by Drs. Luis Reyes and Deborah Doroshow, reviewed key thoracic oncology updates in targeted therapy, immunotherapy, and small cell lung cancer (SCLC), with CME information and audience Q&A.<br /><br />Dr. Melinda Su summarized major targeted-therapy highlights. For KRAS G12C, she reviewed the evolving drug landscape, emphasizing that combinations will likely drive future gains, given modest benefits with chemo combinations and prior hepatotoxicity concerns with some immunotherapy pairings. Newer combinations (including SHP2 inhibition) may improve efficacy and tolerability. She also discussed KRAS co-mutations (e.g., STK11, KEAP1, TP53) and mixed evidence on how they affect outcomes with KRAS inhibitors, noting prospective stratification data suggesting STK11 can be a poor prognostic factor. For KRAS G12D, she outlined several investigational inhibitors showing encouraging response rates with generally manageable toxicity. She closed with EGFR exon 20 developments, noting multiple emerging TKIs with activity (including after amivantamab) and generally improved tolerability versus amivantamab.<br /><br />Dr. Tiziana Leal reviewed immunotherapy duration in metastatic NSCLC, supporting 2 years as the current standard, with real-world data suggesting no survival disadvantage versus indefinite therapy and less toxicity. She highlighted ongoing de-escalation trials and emerging bispecific strategies.<br /><br />Dr. Paul Bunn covered new SCLC directions: chemo-immunotherapy as standard, DLL3 bispecific T-cell engagers (notably tarlatamab) with durable benefit in a subset and manageable early CRS/ICANS, trials moving these agents earlier, lurbinectedin maintenance benefits, and promising ADCs (DLL3, TROP2, B7H3, SEZ6). Q&A focused on stopping rules, biomarkers, toxicity, feasibility, and future chemo-sparing approaches.

Keywords

ISLC Best of TTLC 2026 webinar

thoracic oncology updates

KRAS G12C inhibitors

KRAS G12D targeted therapy

EGFR exon 20 TKIs

metastatic NSCLC immunotherapy duration

immunotherapy de-escalation trials

small cell lung cancer chemo-immunotherapy

DLL3 bispecific tarlatamab